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SATURDAY, SEPTEMBER 13, 2014, 5:00 PM–7:00 PM www.jacctctabstracts2014.comResults: Mean age was 64 +/- 11.2 years, 84.4% males, 30.2% diabetics and 59.6%
had unstable angina at inclusion. 54.3% with 3 vessels and ULM, 1.8 +/- 0.3 Firebird-
2 per pt was implanted. Clinical success was accomplished in 100%. At discharge all
pts received DAPT. Complete 6 months follow-up results are reported in Table. In pts
with diabetes, Firebird-2 group also showed a beneﬁt in MACCE compared to ERACI
3-DES p¼0.02 and ERACI 3-CABG p¼0.04.6 months outcome
ERACI 4
ERACI 3-
DES
ERACI 3-
CABG
ERACI 4
vs ERACI
3-DES
ERACI 4
vs ERACI
3- CABG
N patients 225 225 225
Death 1 (0.4%) 6 (2.7%) 15 (6.7%) 0.05 <0.001
Myocardial
Infarction (MI)
1 (0.4%) 5 (2.2%) 14 (6.2%) 0.1 0.001
Non-fatal
Cerebrovascular
accident (CVA)
0 (0%) 1 (0.4%) 2 (0.9%) 0.31 0.15
Death/MI/CVA 2 (0.9%) 9 (4.0%) 31 (13.8%) 0.03 <0.001
Target vessel
revascularization
(TVR)
2 (0.9%) 13 (5.8%) 5 (2.2%) 0.004 0.25
MACCE (Death/
MI/CVA/TVR)
4 (1.8%) 17 (7.6%) 36 (16.0%) 0.004 <0.001Conclusions: At 6 months this multicenter and prospective registry showed that
Firebird 2 had a remarkable low incidence of MACCE and death/MI/CVA either
compared to CABG or 1st DES arms,Firebird 2 also had lower TVR rate than 1st
DES.
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Background: The ION Registry assessed clinical outcomes for the thin-strut, ION
(TAXUS Element) Paclitaxel-Eluting Platinum Chromium Coronary Stent System
(Boston Scientiﬁc, Natick, MA) in unselected patients at 40 sites in the United
States. Two-year “real world” results with this stent have not been previously
reported.
Methods: This prospective, open-label registry enrolled 1120 consenting all-
comer patients treated with the ION stent for any indication at each site. Follow-
up was at discharge, 30 and 180 days, and annually to 5 years. The primary
endpoint was the 1-year rate of cardiac death or MI in PERSEUS-like patients (ie,
patients who met the enrollment criteria for the pivotal PERSEUS trial; JACC
2010;56:264–71). Per protocol, the primary endpoint result from the ION registry
was also combined with the EU post-approval registry (TE-PROVE), which
enrolled 306 PERSEUS-like patients, and the PERSEUS WH/SV populations
(N¼1166).
Results: Among 1111 patients who received a study stent, most (70.3%, 781/
1111) were male, with a mean age of 64.111.0 years, and 316 were PERSEUS-
like. At 1-year, clinical follow-up or death were recorded in 92.1% (1023/1111).
The primary endpoint of cardiac death or MI at 1 year occurred in 2.1% (6/292)
of PERSEUS-like patients in ION and 2.3% (40/1729) patients in the combined
analysis. The upper 1-sided 95% CI for the combined analysis was 2.9%, which
was signiﬁcantly less than the prespeciﬁed performance goal of 7.6% (P<
0.001). Additional 1-year clinical endpoint rates were 9.4% (97/1028) MACE
(deﬁned as cardiac death, MI, TVR), 2.0% (21/1028) cardiac death (0.4% related
to ION stent), 3.0% (31/1028) MI (1.9% related to ION stent), 6.8% (70/1028)
TVR (4.9% related to ION stent), and 2.1% (22/1028) ARC deﬁnite/probable ST
(2.0% related to ION stent).
Conclusions: The 1-year results of the ION US Post-Approval Study conﬁrm the
safety and effectiveness of the ION stent for the treatment of coronary artery disease in
everyday clinical practice. Two-year overall results and results from selected subsets
of this real-world population (diabetes, small vessels, long lesions) will be available
for the ﬁrst time at TCT 2014.B168 JACC Vol 64/11/Suppl B j SeTCT-579
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Background: It remains unclear whether there are differences in the safety and ef-
ﬁcacy outcomes between Cobalt Chronium (CoCr-EES) and Platinum Chronium
everolimus-eluting stents (PtCr-EES).
Methods: From the Interventional Cardiology Research In-Cooperation Society-
Drug-Eluting Stents Registry, we identiﬁed 6065 consecutive patients who received
CoCr-EES (3080 patients) and PtCr-EES (2985 patients). We compared major
adverse cardiac events (MACE) which was deﬁned using a composite measure
consisting of death, nonfatal myocardial infarction, or target vessel revascularization
(TVR) with the use of propensity-score matching in the overall cohort according to
type of stents.
Results: At 2-years of clinical follow-up, the 2 study groups (2510 patients for each
propensity-score matched group) did not differ signiﬁcantly in crude risk of the
MACE (12.0% for CoCr-EES versus 11.6% for PtCr-EES; HR, 0.954; 95% CI, 0.81 –
1.13, p¼0.581). There was also no differences between the stent groups in the risks of
the individual component of death (HR, 1.083; 95% CI, 0.786 – 1.492, p¼0.624), MI
(HR, 0.972; 95% CI, 0.770 – 1.228, p¼0.812), and TVR (HR, 0.798; 95% CI, 0.598 –
1.065, p¼0.125). The risk of cerebrovascular event (HR, 0.914; 95% CI, 0.566 –
1.477, p¼0.714) and deﬁnite stent thrombosis (HR, 1.000; 95% CI, 0.290 – 3.454,
p¼1.000) were also similar between the two groups.Conclusions: The use of CoCr-EES and PtCr-EES showed similar rates of safety and
efﬁcacy outcomes with regard to death, MI, stent thrombosis and TVR.
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Background: The TE-PROVE post-market registry has enrolled 1014 patients at 37
sites in the EU to evaluate real-world clinical outcomes for patients receiving the
paclitaxel-eluting, platinum chromium TAXUS Element stent (Boston Scientiﬁc,
Natick, MA). This is the ﬁrst report of 2-year outcomes with the TAXUS Element
stent in everyday clinical practice.
Methods: The primary endpoint of overall and study stent-related target vessel failure
(TVF, deﬁned as cardiac death, and target vessel-related MI and reintervention [TVR])
at 1 year post-implantation was 6.0% (59/987), of which 3.7% (37/9874) was
considered related to the study stent (Tamburino et al, TCT 2013). Follow-up in TE-
PROVE will continue annually through 5 years. Secondary endpoints included the
components of TVF, all-cause mortality, and ARC deﬁnite/probable stent thrombosis.
An independent Clinical Events Committee adjudicated all events for relatedness to
the study stent.
Results: At baseline, 75.0% (760/1014) of patients were male, mean age was
65.110.8 years, 25.5% (259/1014) had medically treated diabetes, mean lesion
length was 19.812.0mm, and mean reference vessel diameter was 3.10.5 mm. At 2ptember 13–17, 2014 j TCT Abstracts/Stents - Drug-eluting: Registries
